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Background and Aim. Crohn’s disease is associated with gut microbiota (GM) dysbiosis. Treatment with the anti-IL-12p40
monoclonal antibody (12p40-mAb) has therapeutic effect in Crohn’s disease patients. This study addresses whether a 12p40-mAb
treatment influences gut microbiota (GM) composition in mice with adoptive transfer colitis (AdTr-colitis).Methods. AdTr-colitis
micewere treatedwith 12p40-mAb or rat-IgG2a orNaCl fromdays 21 to 47. Disease wasmonitored by changes in bodyweight, stool,
endoscopic and histopathology scores, immunohistochemistry, and colonic cytokine/chemokine profiles. GM was characterized
throughDGGE and 16S rRNA gene-amplicon high-throughput sequencing. Results. Following 12p40-mAb treatment, most clinical
and pathological parameters associated with colitis were either reduced or absent. GM was shifted towards a higher Firmicutes-
to-Bacteroidetes ratio compared to rat-IgG2a treated mice. Significant correlations between 17 bacterial genera and biological
markerswere found.The relative abundances of the RF32 order (Alphaproteobacteria) andAkkermansiamuciniphilawere positively
correlated with damaged histopathology and colonic inflammation. Conclusions. Shifts in GM distribution were observed with
clinical response to 12p40-mAb treatment, whereas specific GM members correlated with colitis symptoms. Our study implicates
that specific changes in GMmay be connected with positive clinical outcomes and suggests preventing or correcting GM dysbiosis
as a treatment goal in inflammatory bowel disease.
1. Introduction
Inflammatory bowel disease (IBD) arises from a loss of toler-
ance and excessive immune response to commensal bacteria
in a genetically susceptible host, although environmental
factors may influence as well. Ulcerative colitis (UC) and
Crohn’s disease (CD) are themajor forms of IBD affecting the
gastrointestinal tract [1]. Key clinical features of these diseases
include abdominal pain, weight loss, and diarrhea, which can
be hemorrhagic [1–3]. As many as 1.4 million in the United
States and 2.2 million persons in Europe suffer from IBD and
the numbers are increasing [4].
Animal models are widely used to study and explain
the pathological mechanisms of gut inflammation. In order
to study IBD and evaluate anti-inflammatory strategies, a
variety of animal models have been developed and are tra-
ditionally divided into those with spontaneous development
of colitis due to genetic manipulation (e.g., targeted deletion
of the anti-inflammatory cytokine IL-10), chemically induced
colitis (e.g., dextran sulfate sodium (DSS)), hapten-induced
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colitis (e.g., 2,4,6-trinitrobenzene sulfonic acid (TNBS)), and
adoptive transfer (AdTr) models (transfer of T cells from a
donor mouse to a T cell deficient mouse) [5]. Compared to
chemically inducible models of colitis such as those based
upon DSS and TNBS, AdTr of CD4+CD25− T cells into
immune deficient mice more closely reflects the altered
gene expression in human IBD [6]. Mouse models of colitis
induced by AdTr of CD25− depleted CD4+ T cells are highly
suitable for pharmacological testing of new IBD drug candi-
dates because they are easy and fast to perform (compared
to other chronic models, e.g., SAMP-1/Yit) [7, 8], there is no
generation of anti-drug antibodies, and it results in uniform
and highly reproducible clinical and pathological signs of
colitis [9]. Three weeks after adoptive cell transfer most
recipient mice develop clear signs of colitis, characterized by
weight loss, loose stools, increased white blood cell (WBC)
count, and thickened and shortened colon [5].
Anti-IL-12/23p40 monoclonal antibody (mAb) targets
the p40 subunit common to IL-12. IL-12 is formed by two
chains, IL-12p35 and IL-12p40,which together form the active
heteromer IL-12p70 [10], whereas the active heterodimer IL-
23 is formed by IL-12p40 and IL-12p19. Both IL-12 and IL-
23 are produced by monocytes, macrophages, and dendritic
cells in response to microbial stimulation [10]. IL-12 induces
the generation of T helper cells type 1 (TH1) [11], and it
enhances the cytotoxic activities of natural killer (NK) cells
[12] leading to secretion of several cytokines, especially
interferon-gamma (IFN-𝛾) [11]. IL-23 stimulates CD4+ T cells
to differentiate into a novel subset of T helper cells called
TH17 cells. TH17 cells produce proinflammatory cytokines
that enhance T cell priming and stimulate the production
of other proinflammatory molecules such as IL-1, IL-6, and
TNF-𝛼, as well as chemokines resulting in inflammation [13–
15]. CD has been associated with excess cytokine activity
mediated by TH1 and TH17 cells. IL-12 and IL-23 are increased
in patients with CD, but their production is downregulated
after administration of IL-12/23p40 monoclonal antibody [7,
13, 16, 17]. Clinical trials with anti-IL12/23p40 therapy have
shown encouraging results in CD patients not responding to
the first-line biologic treatment, which is anti-TNF-𝛼 mAb.
The reason why anti-IL12/23p40 works particularly well in
this patient segment is currently unknown, but it could be
due to specific genetic alterations, as well as microbiota/gut
interactions common in the IL-12/23p40 pathway driving the
pathogenesis in these patients. Moreover, alterations in gut
microbiota (GM) have been shown as a predictor of relapse
in CD patients [18].
Genetically engineered animal models of IBD do not
develop fulminant colitis under germ-free conditions, but gut
inflammation evolves when they are colonized by bacteria,
which points out the important role of the GM in the initia-
tion and development of colitis [19, 20]. Moreover, antibiotics
may ameliorate experimental colitis even in a therapeutic
setting [7]. Several studies have shown that IBD is accom-
panied by a shift in GM towards higher abundance of
proinflammatory bacteria, such as Enterobacteriaceae, while
the abundance of, for example, lactobacilli and bifidobac-
teria is reduced [21–24]. Furthermore, a number of studies
indicate that GM diversity is reduced in colitis [21, 25, 26].
However, detailed knowledge on how GM composition
changes in relation to colitis is still limited and more studies
are required to verify the alternations in the overall compo-
sition of GM during intestinal inflammation and to which
extent such alternations are of importance in a preventive or
therapeutic intervention. Identifying relevant links between
GM composition and clinical parameters of colitis is also of
great importance.
Consequently, the aimof the present studywas to evaluate
how microbiota composition in colonic content correlated
with clinical signs of IBD in mice treated with monoclonal
anti-IL12/23p40 antibody (12p40-mAb) in an adoptive T cell
transfer model of colitis (AdTr-colitis).
2. Materials and Methods
2.1. Mice. All experiments were conducted in accordance
with the European Communities Council Directive 86/609/
ECC for the protection of animals used for experimental
purposes, approved by the Danish Animal Experiments
Inspectorate, Ministry of Food, Fisheries and Agriculture,
Denmark, and the internal Ethical Review Council at Novo
Nordisk A/S.
C.B-Igh-1b/IcrTac-Prkdcscid (C.B-17 SCID) and BALB/
cAnNTac female mice (8–10 weeks) bred under barrier pro-
tected conditions (Taconic, Ll. Skensved, Denmark) were
housed at Novo Nordisk A/S. Mice were identified using
Plexx microchips (Plexx, Elst, Netherlands) and were ran-
domized in the cages to reduce cage effects. Dirty cage
bedding was transferred to the individual cages before the
experiment was initiated as well as once weekly during the
experiment. Health monitoring was performed according to
FELASA guidelines [27].
2.2. Purification of Cells and Induction of Colitis. Colitis was
induced by AdTr of CD4+CD25− T cells (AdTr-colitis) from
spleen of MHC-compatible BALB/c mice to C.B-17 SCID
recipients as previously described [9]. Briefly, splenocytes of
BALB/c donor mice were subjected for positive selection of
CD4+ T cells using Dynabeads and DETACHaBEAD (Life
Technologies Europe, Ballerup, Denmark) and depletion of
CD25+ from the CD4+ T cell suspensions using the CD25
MicroBead kit. Flow cytometry was used to analyze purity
of the cells and showed that more than 98% of the CD4+
cells were CD25− cells. Each recipient was reconstituted with
300,000 cells by intraperitoneal injection. Two or three weeks
after transfer, peripheral blood from all mice was analyzed by
flowcytometry for the presence ofCD4+ Tcells.Only animals
with successful transplantation of cells were included in the
study.
2.3. Experimental Groups. The mice were divided into four
groups. One group of nontreated C.B-17 SCID mice (SCID
control) were not subjected to AdTr-colitis (𝑛 = 4), while
the three groups of adoptively transferred C.B-17 SCID mice
were treated with a neutralizing rat anti-mouse IL-12/23p40
monoclonal antibody (12p40-mAb) (clone C17.8) (𝑛 = 15) or
rat-IgG2a monoclonal isotype antibody (clone 2A3) (𝑛 = 13)
or NaCl (𝑛 = 14) from day 21 until termination at day 47.
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The antibodies were purchased from Bio X Cell (New
Hampshire, USA) and had been tested for endotoxins. The
antibodies were injected intraperitoneally three times weekly
and dosed according to body weight at 25mg kg−1.
2.4. Monitoring of Disease. Animals were weighed three
times per week andmice that lostmore than 20% of the initial
weight were sacrificed. Fecal samples were evaluated and
scored from 0 to 4 according to their consistency (normal
stool = 0; slightly soft stool = 1; soft but formed stool = 2; not
formed stool = 3; liquid stools or no feces in the colon at sac-
rifice = 4). Disease activity index score (DAI) was calculated
based on data obtained fromweight loss and feces type as pre-
viously described byMurthy et al. [28]. As fecal blood is rarely
observed in AdTr-colitis it was not monitored. Mice were
anaesthetized by isoflurane (Isoba Vet, MSD Animal Health,
Ballerup, Denmark) and blood was obtained by retroorbital
puncture. All blood samples were collected in EDTA K2
coated microtubes (Milian, Gahanna, Ohio, USA). EDTA-
stabilized peripheral whole blood samples (20 𝜇L) were used
for monitoring the number of white blood cells (WBC)
per liter with Medonic CA 620 (Boule Nordic, Denmark)
blood analysis apparatus according to the manufacturer’s
protocol. Colonoscopy was performed on days 21 and 34.
Mice were anaesthetized with isoflurane and placed in dorsal
recumbency. A rigid telescope (HOPKINS Straight Forward,
0∘) was connected to a light source/air pump (Xenon 175) and
camera (Telecam SL) as described by Becker et al. [29] The
endoscope (2mm) was coated with a lubricant containing
lidocaine hydrochloride (Farco-Pharma, Ko¨ln, Germany)
and introduced via the anus into the distal 4 cm of the colon.
The evaluation of the colonoscopic findings was done by
two blinded observers using the murine endoscopic index of
colitis severity (MEICS) score (Supplemental Table 1 in Sup-
plementary Material available online at http://dx.doi.org/10
.1155/2016/4953120), as outlined by Becker et al. [30].
2.5. Postmortem Analysis. Mice were sacrificed by cervical
dislocation on day 47. However, one mouse in the rat-IgG2a
group was sacrificed at day 45 due to severe weight loss. After
the animals were sacrificed the colon was excised and opened
longitudinally. Fecal and colonic content was collected in a
sterile Eppendorf tube and tissuewas gently rinsedwith saline
and its weight (𝑊, mg) and length (𝐿, cm) were measured.
The left halves of colon were used for cytokine measurements
and the right halves were fixed on a plastic plate with pins and
processed for histological analysis. Cecumwas excised and its
contents were collected in sterile Eppendorf tubes.
2.6. Histology. Tissue for histology was fixed in 4% para-
formaldehyde (VWR-Bie & Berntsen, Herlev, Denmark) for
approximately 24 hours at 4∘C. Subsequently, the samples
were transferred to 70% ethanol and stored at 4∘C until pro-
cessed for histopathology. The samples were processed in a
Leica Asp300S histoprocessor (LeicaMicrosystems, Ballerup,
Denmark) overnight, embedded in paraffin blocks using
a Shandon Histocentre 3 (Thermo Electron Corporation,
Marietta, Ohio), and sectioned at a thickness of 3 𝜇m in
a Leica Microtome RM 2165 (Leica Microsystems, Ballerup,
Denmark). Subsequently, the slides were stained with hema-
toxylin (Ampliqon, Skovlunde, Denmark) and eosin (Sigma-
Aldrich, Brøndby, Denmark) (H&E) for light-microscopic
examination, Olympus Ax70 microscope. The severity of the
histopathological lesions of colon segments was examined in
a blindedmanner, using the criteria described in Supplemen-
tal Table 2.
For immunohistochemical (IHC) detection of CD3 or
S100A8 (calprotectin) paraformaldehyde fixed colon sections
were mounted on adhesive slides (Superfrost Plus, Menzel-
Gla¨ser, Germany) dried at 60∘C and kept at 4∘C until pro-
cessed. Tissue sections were processed through xylene and
rehydrated. For CD3 IHC the tissue sections were boiled in
Tris-EGTA buffer and quenched with H
2
O
2
(0,5%). Tissue
sections were blocked (with goat and mouse serum, BSA,
and skim milk) and slides were incubated with polyclonal
rabbit anti-human CD3 antibody (RM-9107-S; SP7, Thermo
Scientific). After washing in TBS buffer secondary antibody-
polymer complex (Envision, K4003) was applied.Then, slides
were developed with diaminobenzidine (DAB) and counter-
stained in Meyer’s hematoxylin and mounted with Pertex.
For calprotectin IHC staining the tissue sections were
boiled in citrate buffer and quenched with H
2
O
2
(0,5%).
Endogenous biotinwas blocked using an avidin-biotin block-
ing kit. Nonspecific binding was blocked by incubation with
TBS containing skimmed milk, donkey serum, and mouse
serum. The primary antibody (Rat-a-Mo S100A8 (MRP-8),
MyBiosource) and secondary antibody (Biotin-SP Donkey
Anti-Rat IgG, Jackson ImmunoResearch) were diluted in
Tris-buffer containing skimmedmilk and donkey andmouse
sera and incubated for 60min each at room temperature.
Next, an amplification step was performed by incubation
with Vectastain ABC Peroxidase Kit for 30min followed
by a chromogenic reaction with DAB. Nuclei were coun-
terstained with Meyer’s hematoxylin and the sections were
rehydrated, cleared in xylene, and mounted with Pertex.
Control immunostainings were run without the primary
antibody and with a nonsense polyclonal antibody of the
same concentration as the primary antibody for both CD3
and calprotectin.
Automated digital image analyses were performed on the
IHC positive areas using the Visiopharm Integrator System
(VIS, version 4.5.1.324, Visiopharm, Hørsholm, Denmark).
On individual digital images of the proximal and distal colon
sections, a region-of-interest (ROI)was automatically defined
of both colon sections using 𝐾-means clustering classifi-
cation. Subsequently, an analysis was run using threshold
classification inside theROI to detect the brownDAB staining
of the specific calprotectin IHC immunostaining. The results
are given as area stainedwithCD3or calprotectin of the entire
colon sections (%).
2.7. Cytokine Measurements. Tissue for cytokine analysis was
weighed and transferred to individual 3.6mL CryoTubes
containing Tissue Homogenate Lysis Buffer (Ampliqon,
Skovlunde, Denmark). The buffer was a solution of 200mM
NaCl, 5mM EDTA, 10mM Tris, 10% glycerin, 1mM PMSF,
1 𝜇gmL−1 leupeptin, and 28𝜇gmL−1 aprotinin (pH 7.4).
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The buffer was kept cold (approx. 4∘C) at all times. The tubes
were immediately snap-frozen in liquid nitrogen and stored
at −80∘C until homogenized. Using an Ultra-Turrax T25
basic disperser (IKA-Werke, Staufen, Germany) the colon
segments were homogenized and the homogenates were
centrifuged three times for 15min at 10,000×g and 4∘C, twice
in Eppendorf tubes and the last time in an Ultrafree MC-
Centrifugal Filter device, 5 𝜇m pore size (Millipore, Billerica,
Massachusetts, USA). The supernatants were analyzed for
levels of colonic cytokines and chemokine using Milliplex
(Millipore, Billerica, Massachusetts, USA). The assays were
run according to the manufacturer’s guidelines with the
exception that the standard and test samples were diluted
in the Tissue Homogenate Lysis Buffer rather than the kit-
supplied assay diluents.
2.8. Gut Microbiota Characterization. Cecal, colonic, and
fecal contents collected at euthanasia were homogenized
three times for 20 sec at speed 5.5m/sec prior to extraction
using a Bead Beater (FastPrep-24, MP Biomedicals, Santa
Ana, USA). DNA was extracted using the QIAamp DNA
Stool Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Concentration and quality of
the extracted DNA were measured using a NanoDrop 1000
Spectrophotometer (Thermo Scientific, USA). A preliminary
screening of the GM diversity (based on profiles of 16S
rRNA amplicons) of cecal, colonic, and fecal contents was
performed using denaturing gradient gel electrophoresis
(DGGE) as outlined in Pyndt Jørgensen et al. [31]. Only DNA
extracted from colon contents was subjected to high-
throughput sequencing (Illumina MiSeq). The V3-V4 region
of the 16S rRNA gene (amplicon size ∼460 bp) was amplified
with primers including adapters for the Nextera Index Kit
(Illumina, California, USA). The primers sequences, condi-
tions for amplification and tagmentation (1st and 2nd round
of PCR), purification, and sequencingwere performed as pre-
viously described [31]. Pair-ended reads (with corresponding
quality scores) were trimmed and merged using the CLC
GenomicWorkbench 7.0.4 (CLC bio, Aarhus, Denmark) [31].
The UPARSE algorithm [32] was used for OTU clustering
(97%) and filtering of chimeric sequences, while the Green-
Genes database 97% (version 12.10)was used forOTUpicking
[33]. The dataset was further analyzed using the Quantitative
Insight Into Microbial Ecology (QIIME versions 1.7.0 and
1.8.0) [34].
Relative quantification of Akkermansia muciniphila was
carried out as previously described [35]. Briefly, the reaction
mixture (20𝜇L) contained 10 𝜇L of 1x SYBR green PCRMas-
ter Mix (Applied Biosystems), 1𝜇L of either A. muciniphila
specific-primers or 16S rRNA universal primers (each primer
was used at a final concentration 0.5𝜇M), 4 𝜇L of nuclease-
free water, and 5 𝜇L of DNA template (20 ng𝜇L−1). The
temperature profile for qPCR was as follows: 95∘C for 5min
and 40 cycles of 95∘C for 15 s and 60∘C for 1min. For
generation of the standard curve, serial tenfold dilutions of
A. muciniphila DSMZ 22959 genomic DNA were used.
2.9. Statistical Analyses. General statistical analyses were
carried out using GraphPad Prism version 5.01 (GraphPad
Software, La Jolla, California, USA). Unpaired Student’s 𝑡-test
was used when comparing the means of normally distributed
parametric data from two groups and aMann-Whitney𝑈 test
was performed when comparing non-Gaussian distributed
data from two groups.When three ormore groups with para-
metric data were compared one-way ANOVA was used with
Tukey’s posttest. The Kruskal-Wallis with Dunn’s posttest
was used on multiple datasets that did not assume Gaussian
distributions. For high-throughput sequencing, the number
of sequences used for subsample (−𝑒 value, Alpha and Beta
Diversity; −𝑑 value, multiple rarefactions) was set to 90%
of the most indigent sample. The Jackknife Beta Diversity
workflow was used to generate PCoA plots (based on 10
distance matrices that were determined using 10 subsampled
OTU tables). Differences between categories in UniFrac
distance matrices were assessed with analysis of similarities
(ANOSIM). Alpha Diversity was measured and expressed as
observed species (97% similarity OTUs) and computed with
10 rarefied OTU tables. Comparison of Alpha Diversities was
made through nonparametric 𝑡-test method (Monte Carlo,
999 permutations). The occurrence and absence of OTUs
associated with a given group of mice were assessed with
the 𝐺-test of independence, whereas differences in the abun-
dance of OTUs were tested with ANOVA. Finally, differences
in the relative abundance of A. muciniphila determined by
qPCR were evaluated using two-tailed Student’s 𝑡-test.
3. Results
3.1. Monitoring of Disease (DAI Score, Weight Change, and
Pathology). The CD4+CD25− T cell transfer was well tol-
erated by the mice, and no adverse events directly related
to 12p40-mAb, rat-IgG2a isotype control, or NaCl were
detected. Mice were randomized according to body weight
(BW) on day 19. No apparent signs of disease were observed
within the first twoweeks after AdTr-colitis (data not shown).
The change in BW over the course of the experiment from
days 21 to 47 is shown in Figure 1(a). Mice started to lose
weight in the 3rd-4th week following transfer.Theweight loss
progressed until the termination of the study. Mice treated
with 12p40-mAb did not show any apparent weight loss and
were similar to SCID control mice, whereasmice treated with
the isotype control and NaCl developed severe weight loss
(𝑝 < 0.0001 and 𝑝 < 0.0007). No significant differences were
observed between NaCl and rat-IgG2a treated groups. The
disease activity index (DAI) is a combined index from 0
to 8 containing weight loss (score 0–4) and stool score
(score 0–4), which gives an overall evaluation of the disease
intensity during the study. DAI was significantly lower in
mice treated with 12p40-mAb compared to rat-IgG2a (𝑝 <
0.001) and NaCl (𝑝 < 0.006) (Figure 1(b)). In animal models
of AdTr-colitis, disease can be associated with thickening
and shortening of the colon wall as a host inflammatory
response. As expected, the colon𝑊 : 𝐿 ratio was increased in
mice receiving NaCl and rat-IgG2a. A significant treatment
effect was observed with the 12p40-mAb compared to the
isotype treated group (𝑝 < 0.0002) and NaCl (𝑝 < 0.0009)
(Figure 1(c)), whereas no differences were observed between
their controls groups.
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Figure 1: Induction of AdTr-colitis is associated with weight loss, loose stools, and colonic inflammation. (a) Delta weight loss from day 21
is shown as mean ± SEM for individual groups. Significant differences between the areas under the curve (AUC) for individual mice were
determined by Student’s 𝑡-test. (b) DAI was determined with a combined scale from 0 to 8 by combining weight loss (0–4) and stool score
(0–4). Differences in DAI scores were calculated as AUC for individual mice from 21 to 45 days using Mann-Whitney 𝑈 test. (c) The colon
weight- (mg) to-length (cm) ratio was calculated for individual mice. Comparisons between groups were performed using Student’s 𝑡-test.
(d) Endoscopic analysis of colon at 21 and 34 days was graded with MEICS. All mice were scored semiquantitatively in a blinded fashion.
Significant differences were determined with Mann-Whitney 𝑈 test for unpaired analysis and Wilcoxon for paired analysis.
Endoscopic pictures were acquired for monitoring and
grading inflammation using MEICS (encompassing the
thickening of the colon, changes of vascular pattern, visible
fibrin, granularity of mucosal surface, and stool consistency).
After randomization but prior to treatment (day 21), the
majority of mice had clear signs of colonic inflammation;
nevertheless, no significant difference between the groups
could be detected (Figure 1(d)). At day 34, however, mice
treatedwith the 12p40-mAb had a significant reduction in the
endoscopic score, compared to mice treated with rat-IgG2a
(𝑝 < 0.004) and NaCl (𝑝 < 0.0008). No differences were
observed between the 12p40-mAb treated and healthy SCID
control mice. Similarly, no difference was observed between
the rat-IgG2a and NaCl treated mice at day 34 (Figure 1(d)).
When comparing disease progressions within the groups
at day 21 versus day 34, mice treated with rat-IgG2a and
NaCl increased their endoscopic score, from day 21 to day
34 (both 𝑝 < 0.03). In comparison, mice treated with the
IL12p40-mAb showed signs of disease amelioration, 𝑝 < 0.09
(Figure 1(d)).
3.2. Histopathology and Immunohistochemical Staining. At
day 47, a significant reduction in histopathology scores was
observed in mice treated with 12p40-mAb compared to the
corresponding isotype control (𝑝 < 0.0001) and NaCl (𝑝 <
0.0008) (Figures 2(a) and 2(d)), while no significant differ-
ences were observed between the control groups. Since path-
ogenic CD4 T cells drive disease progression in AdTr-colitis,
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Figure 2:Histology and immunohistochemistry of representative areas ofmouse colon.The left panel (a, b, c) shows the histopathological and
IHC evaluation of the colon. After H&E staining (a), the 12p40-mAb treated mice had normal morphology as seen in the SCID control mice.
Rat-IgG2a and NaCl treated mice had major hyperplasia of the mucosal layer and infiltration of immune cells. The CD3 (b) and calprotectin
(c) IHC identify these immune cells as being CD3 or calprotectin positive cells as visualized with the brown DAB staining of the positive cells
in the mucosa layer and submucosa. The scale bar indicates 200 𝜇m and all images are captured at 20x magnification. The images are from
the mouse with the results representing the group median for the specific staining of the four mice groups. The right panel (d, e, f) depicts
the results from the histopathological (d) evaluation using a semiquantitative score (range 0–24). CD3 (e) and calprotectin (f) staining were
quantitatively assessed by digital image analysis; data is represented as the density of the IHC reactivity (%).
colonic sections were stained for a T cell marker (CD3). The
percentage of CD3 stained colon tissue was then used to
monitor the effect of 12p40-mAb on colonic T cell inflam-
mation.Mice treatedwith 12p40-mAb had significantly lower
density of CD3 as compared to the isotype control and NaCl
(𝑝 < 0.0001 and 𝑝 < 0.0008, resp.) (Figures 2(b) and 2(e)).
Calprotectin is primarily found in the cytosol of neutrophils
and is dramatically upregulated in areas of inflammation,
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Table 1: Cytokine and chemokine levels in colon.
pg/100mg colonA Mice group Significance Significance
SCID healthy control 12p40-mAb rat-IgG2a 12p40-mAb versus rat-IgG2a 12p40-mAb versus SCID
CCL5 192 ± 72 229 ± 35 493 ± 62 <0.001 0.600
IL-2 182 ± 24 156 ± 19 95 ± 11 0.010 0.430
IL-5 69 ± 15 118 ± 37 31 ± 3 0.020 0.400
IL-9 1,489 ± 180 1,379 ± 194 683 ± 97 0.004 0.730
IL-10 164 ± 30 156 ± 22 91 ± 10 0.010 0.840
IL-13 932 ± 145 763 ± 122 392 ± 52 0.009 0.430
IP-10 926 ± 567 965 ± 180 3,446 ± 606 <0.001 0.930
KC 224 ± 44 167.5 ± 31 440 ± 61 <0.001 0.310
TNF-𝛼 28 ± 5 24 ± 5 60 ± 7 <0.001 0.630
ACytokine and chemokine levels in colon were evaluated by Luminex assay and are depicted as pg per 100mg colon tissue. Only three of the study groups were
included in the analysis (12p40-mAb, rat-IgG2a, and SCID control mice).
whereas it is seldom observed in healthy tissue. Compared
to the isotype control and NaCl treatments, mice treated with
12p40-mAb had lower density of calprotectin (or neutrophil
inflammation) in the colon (𝑝 < 0.001 and 𝑝 < 0.0045,
resp.) (Figures 2(c) and 2(f)). No significant differences were
determined between the control groups.
3.3. Cytokines. Total colonic cytokine/chemokine levels were
determined in colon biopsies from mice treated with 12p40-
mAb or rat-IgG2a or healthy controls. Several proinflam-
matory cytokines and chemokines (TNF-𝛼, CCL5, IP-10,
and KC) were significantly elevated in mice treated with
rat-IgG2a compared to 12p40-mAb treated mice (Table 1).
The cytokine/chemokine levels in 12p40-mAb treated mice
were not different from the healthy control mice (Table 1).
Moreover, mice treated with 12p40-mAb had significantly
higher levels of TH2 (IL-5, IL-9, and IL-13) and the immuno-
suppressive cytokine IL-10 compared to rat-IgG2a treated
mice (Table 1). Thus, different T cell environments may be
induced by the two treatment settings.
3.4. Gut Microbiota Composition. Significant changes of 16S
rRNA amplicons profiles, based on denaturing gradient gel
electrophoresis (DGGE), were observed within gut contents
of the NaCl and 12p40-mAb treated mice (Supplemental
Figure 1). Since significant differences between the colon
contents of 12p40-mAb and rat-IgG2a were also observed,
the DNA from colonic contents was subjected to high-
throughput sequencing (Illumina MiSeq). The number of
reads obtained by sequencing of 16S rRNA gene (V3-V4
region) amplicons from 32 colonic fecal samples was 1,697,168
(mean sequence length of 341 bp). After preprocessing (trim-
ming, quality control, sorting, and chimera filtering), the
number of high quality reads obtained was 990,505, whereas
the number of sequences per sample varied from 14,534 to
61,423 (average of 30,953 ± 9,561). The estimated average
number of observed OTU-species in the 12p40-mAb treated
group (𝑛 = 9), SCID control (𝑛 = 3), rat-IgG2a treated group
(𝑛 = 9), and NaCl group (𝑛 = 11) was not significantly
different [a reduced number of samples were subjected to
sequencing due to limited sequencing capacity; samples were
randomly selected and all treatments were represented] (𝑡-
test, 𝑝 > 0.05; Supplemental Table 3). Similarly, no differ-
ences in Beta Diversity were observed between the 12p40-
mAb and SCID control (nonactive disease) or between the
isotype and NaCl treated mice (active colitis) (ANOSIM,
𝑝 > 0.05). Principal coordinate analysis of weighted UniFrac
distance matrices, however, showed significant separation
of the nonactive disease and active colitis mice (ANOSIM,
𝑝 < 0.01, weighted 𝑟 = 0.18; Figure 3). Furthermore, their
GM showed changes in the relative abundance of 7 genera
(Table 2) [not statistically different after correcting for multi-
ple comparisons] and at the phylum level a significantly lower
(𝑡-test, 𝑝 > 0.05) Firmicutes : Bacteroidetes ratio was seen in
the colitis active mice (0.30) as compared to the nonactive
disease mice (0.83) (however, when only 12p40-mAb and
rat-IgG2a were compared no significant differences were
observed, putatively due to low number of observations and
high intersample variation). Such lower relative abundance
of operational taxonomic units (OTUs) assigned to phylum
Firmicutes was partially caused by a drop in the relative abun-
dance of Clostridiales from 34.5% to 15.9% (constituted by
members of Ruminococcus, Oscillospira, and an unclassified
genus).
3.5. Correlation of Gut Microbiota Composition to Disease
Parameters. Seventeen genus-level OTUs correlated either
positively or negatively with changes in host parameters (Fig-
ure 4 and Supplemental Table 4). Within highly abundant
members, Bacteroides (with a range in relative distribution of
1.5–89%) showed strong positive correlations with most host
parameters (with exception of weight AUC) as well as inverse
correlations against IL-2, IL-9, and IL-13. Two unclassified
genera of Clostridiales (1.2–63%, unclassified Clostridiales
and unclassified Lachnospiraceae), Oscillospira (0.1–8.5%),
and S24-7 family (3–60%) correlated only negatively with the
host parameters, while the latter group correlated positively
with IL-2, IL-9, IL-10, and IL-13 (Figure 4). The rest of the
OTUs that showed significant correlations did not exceed 15%
of relative distribution.
Upon categorization of host parameters (intervals scores)
the prevalence of two OTUs at the genus-level, assigned
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Table 2: Changes in taxa abundance between active colitis (rat-IgG2a andNaCl) and nonactive disease (12p40-mAb and healthy) determined
by ANOVA.
Phylum Class Order Family Genus
Relative distribution Significance
Active
colitis
Nonactive
disease 𝑝 value 𝑞-value
A
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 37.19% 11.32% 0.002 0.060
Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] Unclassified 0.14% 0.05% 0.004 0.072
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 0.47% 3.89% 0.004 0.054
Firmicutes Clostridia Clostridiales Unclassified Unclassified 13.22% 26.45% 0.010 0.100
Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 2.20% 4.21% 0.029 0.225
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides 0.68% 0.15% 0.044 0.288
TM7 TM7-3 CW040 F16 Unclassified 0.01% 0.02% 0.045 0.249
A
𝑞-values were determined with the False Discovery Rate correction method.
PC
1 
(1
4%
)
PC2 (61%)
Figure 3: Beta Diversity analysis separates nonactive disease [light-
blue] (12p40-mAb [circles] and healthy [squares]) from active colitis
mice [orange] (rat-IgG2a [circles] and NaCl [squares]). PCoA
plot (unscaled) was determined through weighted UniFrac metrics
(ANOSIM, 𝑝 < 0.01, 𝑟 = 0.18) of the colonic microbiota from 32
mice. The ellipsoids highlight the degree of variation around each
sample.
to Akkermansia (relative abundance of 0–7.8% and ≤0.001–
11.6% as determined by Illumina sequencing and species-
specific qPCR, resp.) and an unclassified member of the
RF32 order (0.1 to 9.2%, Alphaproteobacteria related to
Rhodospirillum rubrum), was associated (𝐺-test, 𝑝 < 0.05)
with high histopathology scores (Figure 5). Furthermore,
species-specific qPCR confirmed that an increase in relative
abundance of Akkermansia muciniphila was associated with
high scores of the same host parameter (Figure 5). Likewise,
the prevalence of both bacteria was significantly associated
also with high scores of CD3 density (scores > 2.7), disease
AUC (scores > 39.5), and calprotectin (scores > 0.15). Addi-
tionally, prevalence of RF32 order was also observed in high
scores of colon ratio (>33.7).
4. Discussion
Several studies support a causal role of a dysfunctional
mucosal barrier in the manifestation of IBD. Recent findings
have shed light on themechanisms bywhich intestinal epithe-
lial cells, microbiota, and immune cells interact and react
in such an environment and how loss of normal regulatory
processes may lead to IBD [17–20]. We have focused on the
regulation of GM following treatment with a monoclonal
antibody against IL-12p40 in an AdTr-colitis mouse model,
in which IBD development was clearly prevented by the
treatment. Most clinical and pathological signs in treated
mice were either clearly reduced or not apparent at all. In
other words, mice subjected to both AdTr-colitis and 12p40-
mAb treatments appeared similar to SCID control mice,
whereas mice treated with the isotype antibody developed
severe signs of IBD. Comparable results have been achieved
by others in the DSS model [36]. Changes in GM seem to
be a shared primary phenomenon in both IBD patients and
AdTr-colitis mice, and our results show that treatment with
12p40-mAb restores the GM composition, that is, similar
to SCID mice. In addition, the colonic cytokine response
with increased levels of IL-5, IL-9, IL-10, and IL-13 clearly
shows that it induces a TH2 response, which is expectable
when IL-12/IL-23 is prevented from inducing a TH1/TH17
profile. In contrast to what has been observed in CD patients
[37] and the mice treated with the isotype antibody, rodents
subjected to the 12p40-mAb treatment had a higher ratio
of Firmicutes : Bacteroidetes. Furthermore, in CD patients
a reduction in bacterial diversity as well as lower relative
distribution of bacteria with anti-inflammatory properties
has been reported [18, 38]. In our study, however, the
overall diversity of the GM was not changed by the treat-
ment. Whether dysbiosis or even specific bacterial strains
can be future surrogate markers for inflammation, incom-
plete disease control, relapse, and response remains uncer-
tain. However, caution should be taken when extrapolating
from mouse to human. On the other hand, the increased
Firmicutes : Bacteroidetes ratio in mice treated with 12p40-
mAb was mainly due to the fact that the treated mice
had higher proportion of Clostridiales members, many of
which correlated inversely to clinical symptoms and TNF-𝛼
levels. Clostridium spp. are strong inducers of Foxp3-positive
regulatory T cells in the colonic mucosa of mice [39], and
transfer of a mixture of 17 human Clostridium spp. or related
bacteria to mice also increased their level of regulatory T
cells [40]. This fits nicely with our observation that 12p40-
mAb significantly upregulated IL-10 in colon. In our study,
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Phylum Class Order Family Genus
Bacteroidetes Bacteroidia Bacteroidales Paraprevotellaceae Unclassified
Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] [Prevotella]
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides
Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae Unclassified
Bacteroidetes Bacteroidia Bacteroidales S24-7 Unclassified
Firmicutes Bacilli Lactobacillales Streptococcaceae Lactococcus
Firmicutes Clostridia Clostridiales Unclassified Unclassified
Firmicutes Clostridia Clostridiales Clostridiaceae Unclassified
Firmicutes Clostridia Clostridiales Lachnospiraceae Unclassified
Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus
Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus
Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Unclassified
Proteobacteria Alphaproteobacteria RF32 Unclassified Unclassified
Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella
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Figure 4: Pearson’s correlation of immunological and host parameters with changes in the relative distribution of microbiota members of the
colonic content. On top of the heat map the immunological and host parameters are depicted. The lineages are marked on the right and are
represented by fivemajor taxonomic ranks. Symbols describing significant correlations were defined as follows: for 𝑝 value, + ≤ 0.05 and ++ ≤
0.01. For 𝑞-value (False Discovery Rate correction), ∗ ≤ 0.05 and ∗∗ ≤ 0.01. A matrix containing the 𝑟-values for every significant correlation
is shown in Supplemental Table 4.
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Figure 5: Bacterial prevalence in mice with high and low histo-
pathology scores. Filled marks illustrate scores between 6 and 24,
while empty marks illustrate those between 0 and 2. Sam-
ples in which RF32 (Alphaproteobacteria), Akkermansia (Illumina
sequencing), and A. muciniphila (species-specific qPCR) were
detected are represented by their relative distribution. Samples
that were negative (no bacteria detected) are depicted at the no
detection line. 𝑞-values were determined with the False Discovery
Rate correction method.
an unclassified genus of Clostridiaceae family correlated
positively to clinical symptoms, presence of effector cells
and proinflammatory cytokines, but this is not necessarily
in conflict with the other observations, as there are also a
number of Clostridiales families in mice, which are known
to induce inflammation [41].
Mice treated with 12p40-mAb had lower relative abun-
dance of Bacteroides, and we observed a positive corre-
lation between the abundance of Bacteroides with clinical
symptoms and TNF-𝛼 levels. This is in accordance with
the fact that both B. vulgatus [42] and B. fragilis [43] are
known to induce intestinal inflammation in rodent models.
It is of interest to note that the abundance of Prevotella
correlates positively with IL-10 levels. In the DSS model they
are known to increase severity of IBD [44, 45], but it is
difficult to compare the DSS model with the AdTr model
in this aspect as only few of the IL-10 producing cells are
present in the recipient SCID background, and thus, their IL-
10 levels will be different at baseline. It is well known that
shifts in GM may lead to a change in the TH1/TH2/TH17
balance, which again may prevent symptoms of TH1/TH17
induced diseases such as CD. It, however, seems to be novel
that an anti-TH1/TH17 treatment, such as 12p40-mAb, also
leads GM towards an anti-inflammatory direction. In our
controlled setup, correlations between mice GM members
and biological markers were significantly associated, but
this is seldom the case in humans [18]. On the other hand
some mechanisms seem to be shared despite this lack of
heterogeneity.
Surprisingly A. muciniphila correlated with high expres-
sion of clinical IBD symptoms as determined by histopathol-
ogy. A. muciniphila is a mucin-degrader with high mucinase
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activity [46], which accounts for more than 1% of the bac-
terial cells in human feces [47]. Extracellular vesicles of
A. muciniphila protect against DSS induced IBD in mice
[48], and its prevalence is decreased manyfold in patients
with either UC or CD [49]. Nevertheless, one possible
explanation of our results is that intestinal inflammationmay
induce higher production of mucin that would primarily be
degraded by A. muciniphila [50]. In the azoxymethane/DSS
model of colon cancer A. muciniphila also seems to correlate
to an increased number of colon tumors [51]. The prevalence
of Alphaproteobacteria was found to be associated with high
histopathological scores, they have previously been reported
to be highly prevalent in fecal microbiota of UC patients [52],
and their role in IBDpathogenesis seems to be associatedwith
proinflammatory changes and GM dysbiosis [53].
5. Conclusions
Here we report that 12p40-mAb treatment in an AdTr-colitis
mouse model of colitis leads to GM changes and that specific
GM composition and members correlate with histopatho-
logical changes and cytokine responses. In addition, increas-
ing the proportion of a number of Clostridiales members
seems to be associated with prevention and attenuation of
colitis symptoms. Thus, our results encourage the search for
biomarkers based on GM and prevention or correction of
dysbiosis as a potential treatment in IBD.
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